Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per ...

Globus Medical reported preliminary sales projections for 2024 of $2.52 billion, while Nevro expects revenues between $408 million to $409 million. Globus Medical's acquisition of Nevro will ...

Globus Medical expects the Nevro acquisition to be accretive to its earnings in the second year of operation. Globus Medical expects to report full financial results for 2024 and provide its updated ...

Globus said it anticipates in annual net sales this year to total between $2.8 billion and $2.9 billion. Globus Medical’s financial adviser for the deal is Morgan Stanley & Co. Wyrick Robbins ...

Globus Medical (GMED) also reaffirmed its guidance for 2025 net sales of $2.66B to $2.69B and non-GAAP EPS of $3.40 to $3.50. Following the merger, Globus Medical (GMED) expects 2025 net sales of ...